Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297213 | 0.87 | AR (0.33) | ARSLC40A1L3MBTL1ACHEALDH1A1 | |
| SCHEMBL4014825 | 0.86 | CRHR1 (0.37) | — | |
| SCHEMBL297647 | 0.83 | CRHR1 (0.36) | CYP1A2HTTALDH1A1MAPTMAPK1 | |
| SCHEMBL226938 | 0.79 | CHEK1 (0.42) | L3MBTL1CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL8911526 | 0.78 | — | — | |
| SCHEMBL29861910 | 0.78 | L3MBTL1 (0.43) | ARSLC40A1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL297631 | 0.75 | KDM4E (0.31) | L3MBTL1CYP1A2CYP2C19TDP1SIGMAR1 | |
| SCHEMBL8315877 | 0.74 | CA2 (0.30) | — | |
| SCHEMBL3754251 | 0.73 | TSHR (0.31) | L3MBTL1TDP1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL6455528 | 0.73 | AR (0.33) | ARL3MBTL1TDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136825-A | ANTIDEPRESSANTS AND CENTRAL NERVOUS SYSTEM AGENTS | KNOLL AKTIENGESELLSCHAFT | 2000-10-24 | — | — | US | claimed |
| EP-0948498-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029411-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-09 | — | — | WO | claimed |
| US-4104392-A | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-01 | — | — | US | claimed |
| US-4096255-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-20 | — | — | US | claimed |
| US-4073916-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4072744-A | SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-07 | — | — | US | claimed |
| US-4069329-A | INHIBITION AND SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-17 | — | — | US | claimed |
| US-4062963-A | N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-12-13 | — | — | US | claimed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | claimed |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | LOHSE OLIVIER (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-1501897-B1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF SE (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-7807836-B2 | Preparation of perylen-3,4:9,10-tetracarboxylic dianhydride and also of naphtalene-1,8-dicarboximides | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-05 | — | — | US | disclosed |
| CN-1968927-B | Method for enantiomer selective preparation for quinoline derivative | NOVARTIS AG | 2010-07-21 | — | — | CN | disclosed |
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | LOHSE OLIVIER | 2009-02-26 | — | — | US | disclosed |
| US-4069317-A | INHIBITION AND SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-17 | — | — | US | disclosed |
| US-4069329-A | INHIBITION AND SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
| US-4062963-A | N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-12-13 | — | — | US | disclosed |
| US-4049645-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-20 | — | — | US | disclosed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | HAX1, OPRK1, OPRD1 | AR 2722/4885SLC40A1 4576/4885L3MBTL1 325/4885 |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | OPRM1, OPRD1, HAX1 | AR 2746/4885SLC40A1 4527/4885L3MBTL1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.